GOP senator: 'Right to try' drug bill isn't 'the Wild West'

Sen. Ron JohnsonRonald (Ron) Harold JohnsonHillicon Valley: Lawmakers angered over Border Patrol breach | Senate Dems press FBI over Russian hacking response | Emails reportedly show Zuckerberg knew of Facebook's privacy issues | FCC looks to improve broadband mapping Hillicon Valley: Lawmakers angered over Border Patrol breach | Senate Dems press FBI over Russian hacking response | Emails reportedly show Zuckerberg knew of Facebook's privacy issues | FCC looks to improve broadband mapping Lawmakers demand answers on Border Patrol data breach MORE (R-Wis.) argued on Hill.TV that "right to try" legislation, which gives terminally ill patients access to experimental medical treatments that haven't been approved by the Food and Drug Administration (FDA), is safe and regulated. 

“They’ve already passed Phase 1 Safety [trials]. Now, that isn’t the be-all end-all, but it shows it’s certainly safe enough to continue the clinical trials," Johnson, who is the chief sponsor of the bill, told Kystal Ball and Buck Sexton on "Rising." 

"These are terminal patients, they have no other alternative. They’re facing the end of their life and it’s up to them to assess that risk, working with their doctors,” he continued.

"This isn’t the Wild West, this isn’t snake oil, these are drugs that really are promising, or else the drug manufacturers wouldn’t be engaged in the very expensive FDA process.” 

President TrumpDonald John TrumpDC board rejects Trump Hotel effort to dismiss complaint seeking removal of liquor license on basis of Trump's 'character' DC board rejects Trump Hotel effort to dismiss complaint seeking removal of liquor license on basis of Trump's 'character' Mexico's immigration chief resigns amid US pressure over migrants MORE signed the legislation, which was considered a major priority for congressional Republicans as well as the administration, last May.

Democrats and many public health groups have opposed the measure, saying it gives patients false hope, and could potentially put them in danger. 

“FDA oversight of access to experimental treatments exists for a reason — it protects patients from potential snake oil salesmen or from experimental treatments that might do more harm than good,”  Rep. Frank Pallone Jr. (D-N.J.), the ranking member of the House Energy and Commerce Committee, said. 

— Julia Manchester